| IMMATICS N.V. |
| Niederlande |
| Gesundheit |
| NL0015285941 / A2P72S |
| 4A3 (Frankfurt) |
| FRA:4A3, ETR:4A3, 4A3:GR |
| - |
| https://immatics.com/ |
|
Immatics N.V. is a biotechnology company dedicated to the discovery and development of T-cell redirecting cancer immunotherapies. The company's primary function is to harness the power of the body's immune system to target and eliminate cancer cells,..
>Volltext.. |
| 1102.94 Mio. EUR |
| 665.16 Mio. EUR |
| 37.92 Mio. EUR |
| -208.4 Mio. EUR |
| -216.99 Mio. EUR |
| -1.73 EUR |
| 15.2 Mio. EUR |
| 303.79 Mio. EUR |
| -191.42 Mio. EUR |
| 8.21 |
| -73.87% |
| -913.68% |
| - |
| - |
| - |
| - |
| IMMATICS |
| 17.07.26 |
|